Schedule 1: replaced, on 1 September 2021, by regulation 4 of the Medicines Amendment Regulations (No 2) 2021 (LI 2021/228).
Every reference to a medicine in this schedule applies whether the medicine is synthetic in origin or is from biological or mineral sources.
Unless specific reference is made otherwise, every reference applies also to medicines that are—
•
preparations and admixtures containing any proportion of any substance listed in this schedule:
•
salts and esters of any substance listed in this schedule:
•
preparations or extracts of biological materials listed in this schedule:
•
salts or oxides of elements listed in this schedule.
Unless specific reference is made otherwise, every reference to a medicine in this schedule applies,—
•
if the medicine is an injection or eye preparation, to any concentration of that medicine; and
•
if the medicine is not an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram.
Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol, or element unless specifically stated otherwise.
Part 1 Prescription medicines
Amending or replacing this Part may affect designated prescriber regulations under section 105(1)(q) of the Act.
12
Abrus precatorius; at all strengths
22
Acetylcholine; except in medicines containing 1 milligram or less per litre or per kilogram
23
Acetylcysteine; for injection or inhalation
25
Acetylmethyldimethyloximidophenylhydrazine
27
Aciclovir; except when specified elsewhere in this schedule
33
Aconitum spp; except when specified elsewhere in this schedule
36
Adapalene; except in medicines containing 1 milligram or less per millilitre or gram and when supplied by a pharmacist in a pack containing not more than 30 grams for the treatment of comedo, popular, and pustular acne (acne vulgaris) of the face, chest, or back
43
Adrenal extract; except for dermal use in medicines containing 0.02% or less of ketosteroids
44
Adrenaline; in medicines containing more than 1%
45
Adrenocortical hormones; except adrenal extract for dermal use containing 0.02% or less of ketosteroids
53
Albumin; except human albumin
55
Alclometasone; except when specified elsewhere in this schedule
56
Alcohol; for injection in medicines containing more than 20%
59
Aldosterone; except in medicines containing 10 micrograms or less per litre or per kilogram
76
Allylisopropylacetylurea; at all strengths
82
Alpha1-proteinase inhibitor
97
Amethocaine; except when specified elsewhere in this schedule; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
108
Aminophenazone; at all strengths
109
Aminophylline; except when specified elsewhere in this schedule
123
Amorolfine; except when specified elsewhere in this schedule; except in preparations for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
132
Amygdalin; at all strengths
140
Anchusa officinalis; at all strengths
141
Ancrod and its immunoglobulin antidote
142
Androgenic and anabolic steroidal agents
153
Antazoline; except for ophthalmic use
154
Antibiotic substances; except when specified elsewhere in this schedule
156
Antihistamines; except when specified elsewhere in this schedule
157
Antimony; except in medicines containing 1 milligram or less per litre or per kilogram
163
Apomorphine; except in medicines containing 1 milligram or less per litre or per kilogram
171
Aristolochia spp; at all strengths
172
Aristolochic acid; at all strengths
174
Arsenic; except in medicines containing 1 milligram or less per litre or per kilogram
178
Articaine; except when used as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council
182
Aspirin; except when specified elsewhere in this schedule; for injection; when combined with caffeine, paracetamol, or salicylamide
194
Atropa belladonna; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less of total solanaceous alkaloids per litre or per kilogram
195
Atropine; except when specified elsewhere in this schedule; except when used as an antidote in a device designed for self-injection; except in medicines containing 300 micrograms or less per litre or per kilogram
208
Azatadine; except when specified elsewhere in this schedule
210
Azelaic acid; except when specified elsewhere in this schedule
211
Azelastine; except when specified elsewhere in this schedule
231
Beclomethasone; except when specified elsewhere in this schedule
251
Benzocaine; except when specified elsewhere in this schedule
252
Benzodiazepine derivatives; except when specified elsewhere in this schedule
253
Benzodiazepines; except when specified elsewhere in this schedule
255
Benzoyl peroxide; except when specified elsewhere in this schedule
257
Benzydamine; except when specified elsewhere in this schedule
262
Beta carotene; in medicines containing more than 18 milligrams per recommended daily dose
264
Betaine; for the treatment of homocystinuria
276
Bifonazole; except when specified elsewhere in this schedule
277
Bilastine; except when specified elsewhere in this schedule
281
Bismuth; except for external use in medicines containing 3% or less
283
Bithionol; at all strengths
294
Boron, including borax and boric acid; except in medicines for internal use containing 6 milligrams or less per recommended daily dose; except in medicines for dermal use other than paediatric use containing 0.35% or less; except when present as an excipient
305
Brivaracetam (and its stereoisomers)
310
Brompheniramine; except when specified elsewhere in this schedule
314
Buclizine; except for oral use
315
Budesonide; except when specified elsewhere in this schedule
316
Bufexamac; except in suppositories; except for dermal use in medicines containing 5% or less
318
Buniodyl sodium; at all strengths
328
Butoconazole; except for vaginal use
330
Butyl aminobenzoate; except in medicines for dermal use containing 2% or less
337
Cacalia spp; at all strengths
339
Calcipotriol; except in medicines containing not more than 50 micrograms per gram or per millilitre and when sold in a pack of not more than 30 grams or 30 millilitres by a pharmacist to an adult with mild to moderate psoriasis previously diagnosed by a doctor
343
Calcium polystyrene sulphonate
363
Carbaryl; except for external use in medicines containing 2% or less
366
Carbenoxolone; except for external use
385
Cebaracetam (and its stereoisomers)
415
Cephaelis acuminata; except in medicines containing less than 0.2% of emetine
416
Cephaelis ipecacuanha; except in medicines containing less than 0.2% of emetine
425
Cetirizine; except when specified elsewhere in this schedule
429
Chloral hydrate; except for dermal use in medicines containing 2% or less
433
Chloramphenicol; except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when specified elsewhere in this schedule
441
Chloroform; for anaesthesia; except when specified elsewhere in this schedule
447
Chlorpheniramine; except when specified elsewhere in this schedule
456
Cholera vaccine; except in the form of an oral liquid containing vibrio cholerae when sold in a pharmacy by a registered pharmacist
458
Choline salicylate; except in medicines containing 10% or less and in pack sizes of 15 grams or less
459
Chorionic gonadotrophin; except in pregnancy test kits
463
Ciclopirox; except when specified elsewhere in this schedule
469
Cimetidine; except when specified elsewhere in this schedule
471
Cinchocaine; for injection; for ophthalmic use; for external use in medicines containing more than 0.5%
484
Clemastine; except for oral use
490
Clioquinol; at all strengths
493
Clobetasone; except when specified elsewhere in this schedule
512
Clotrimazole; except when specified elsewhere in this schedule
519
Cocaine; except when specified elsewhere in this schedule
525
Colecalciferol; except in medicines containing 25 micrograms or less per recommended daily dose; except in parenteral nutrition replacement preparations
530
Collagen; in injections or implants for tissue augmentation or cosmetic use
531
Collagenase clostridium histolyticum
533
Conium maculatum; at all strengths
540
Cortisone and other steroidal hormones of the adrenal cortex; except when specified elsewhere in this schedule; except adrenal extract for dermal use in medicines containing 0.02% or less of ketosteroids
541
Cotarnine; at all strengths
544
COVID-19 vaccines; except when administered by vaccinators, registered pharmacists, or registered intern pharmacists who have successfully completed the COVID-19 Vaccinator Education Course (or any equivalent training course on COVID-19 vaccination approved by the Ministry of Health) and who comply with the immunisation standards of the Ministry of Health (but excluding vaccinators who have completed the Provisional Vaccinator Foundation Course or the COVID-19 Vaccinator - Working under Supervision Course)
548
Crotalaria spp; at all strengths
549
Croton tiglium; except in medicines containing 1 milligram or less per litre or per kilogram
553
Cyclizine; except when specified elsewhere in this schedule
558
Cyclopentolate; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
566
Cynoglossum spp; at all strengths
567
Cyproheptadine; except for oral use
594
Datura spp; except for oral use when specified elsewhere in this schedule; except datura stramonium or datura tatula for smoking or burning
605
Dehydrochloromethyltestosterone
613
Deoxycholic acid; for injection; except for oral use
614
Deoxyribonuclease; except for external use
615
Dermatophagoides farina allergen extract
616
Dermatophagoides pteronyssinus allergen extract
622
Desloratadine; except for oral use
625
Desogestrel; except when supplied for oral contraception to women who meet the clinical and eligbility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister or Director-General to their distribution as medicines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme
631
Dexchlorpheniramine; except when specified elsewhere in this schedule
634
Dextromethorphan; except when specified elsewhere in this schedule
638
Di-iodohydroxy quinoline; except when specified elsewhere in this schedule
639
Di-isopropylamine dichloroacetate
644
Dibrompropamidine; except for ophthalmic use
648
Diclofenac; in preparations for the treatment of solar keratosis; except when specified elsewhere in this schedule; except in preparations for topical use other than for the treatment of solar keratosis
664
Digoxin-specific antibody fragment
671
Dimenhydrinate; except when specified elsewhere in this schedule
675
Dimethindene; except for oral use
680
Dimiracetam (and its stereoisomers)
688
Diphemanil; except for dermal use
689
Diphenhydramine; except when specified elsewhere in this schedule
691
Diphenoxylate; except when specified elsewhere in this schedule
693
Diphtheria, tetanus, and pertussis (acellular, component) vaccine; except when administered in a single dose to a person 18 years of age or over or to a pregnant woman aged 13 years or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course)
704
DMHA, including the isomers 2-amino-6-methylheptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexylamine)
709
Doliracetam (and its stereoisomers)
726
Doxylamine; except when specified elsewhere in this schedule
732
Duboisia leichhardtii; except when specified elsewhere in this schedule
733
Duboisia myoporides; except when specified elsewhere in this schedule
742
Econazole; except when specified elsewhere in this schedule
746
Edetic acid; except in medicines containing 0.25% or less; except in contact lens preparations; except dicobalt edetate for the treatment of cyanide poisoning
760
Emetine; except in medicines containing 0.2% or less
790
Ergocalciferol; except in medicines containing 25 micrograms or less per recommended daily dose
799
Erysimum spp; except in medicines containing 1 milligram or less per litre or per kilogram
805
Esomeprazole; except when specified elsewhere in this schedule
813
Ethanolamine; for injection
815
Ether; for anaesthesia; except when specified elsewhere in this schedule
817
Ethinyloestradiol; except when supplied at a strength of 35 micrograms or less in combination with either levonorgestrel or norethisterone for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister or Director-General to their distribution as medicines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme
826
Ethyl chloride; for inhalation
829
Ethylhexanediol; at all strengths
833
Etidronic acid; except in medicines for external use containing 1% or less
837
Etofenamate; except for external use
849
Factor VIII inhibitor bypassing fraction
850
Famciclovir; except when specified elsewhere in this schedule
851
Famotidine; except when specified elsewhere in this schedule
853
Farfugium japonicum; at all strengths
854
Fasoracetam (and its stereoisomers)
857
Felbinac; except for external use
859
Felypressin; except when combined with a local anaesthetic and used in practice by a dental therapist or oral health therapist registered with the Dental Council
872
Fexofenadine; except when specified elsewhere in this schedule
874
Fibrinolysin; except for external use
887
Fluconazole; except when specified elsewhere in this schedule
903
Fluorescein; for injection
904
Fluorides; for internal use in medicines containing more than 0.5 milligrams per dose unit except in medicines containing 15 milligrams or less per litre or per kilogram; except in parenteral nutrition replacement preparations; for external use in medicines containing more than 5.5 grams per litre or per kilogram except when supplied to a dental professional registered with the Dental Council
913
Flurbiprofen; except when specified elsewhere in this schedule
917
Fluticasone; except when specified elsewhere in this schedule
920
Folic acid; except when specified elsewhere in this schedule
921
Folinic acid; except when specified elsewhere in this schedule
922
Follicle-stimulating hormone; except in medicines containing 100 micrograms or less per litre or per kilogram
929
Fonturacetam (and its stereoisomers)
980
Glutathione; for injection
981
Glyceryl trinitrate; for injection; for transdermal use; except in medicines containing 100 micrograms or less per litre or per kilogram
986
Gonadotrophic hormones; except when specified elsewhere in this schedule
993
Growth hormone releasing hormones
994
Growth hormone releasing peptide-6
995
Growth hormone releasing peptides
996
Guaifenesin; except when specified elsewhere in this schedule
1004
Haemophilus influenzae vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds
1009
Haloperidol; except in medicines containing 1 milligram or less per litre or per kilogram
1012
Halquinol; except for external use
1013
Heliotropium spp; at all strengths
1015
Heparins; except when present as an excipient; except for external use
1019
Hexachlorophane; in medicines containing more than 3%; except when specified elsewhere in this schedule
1022
Hexetidine; except for external use
1027
Histamine; except in medicines containing 0.5% or less
1029
Human chorionic gonadotrophin; except in pregnancy test kits
1030
Human growth hormone secretagogues
1031
Human papillomavirus vaccine; except when administered by a registered pharmacist or registered intern pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course)
1033
Hyaluronic acid; in injections or implants for tissue augmentation or cosmetic use
1037
Hydrocortisone; except when specified elsewhere in this schedule
1038
Hydrocyanic acid; except when specified elsewhere in this schedule
1041
Hydroquinone; except when specified elsewhere in this schedule
1049
Hylan polymer; in injections or implants for tissue augmentation or cosmetic use
1050
Hyoscine; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less per litre or per kilogram
1051
Hyoscine butylbromide; except when specified elsewhere in this schedule
1052
Hyoscyamine; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less per litre or per kilogram
1053
Hyoscyamus niger; except when specified elsewhere in this schedule
1054
Hypothalamic releasing factors
1055
Hypromellose; for injection; except in intraocular viscoelastic products
1061
Ibuprofen; except when specified elsewhere in this schedule
1070
Idoxuridine; except for dermal use in medicines containing 0.5% or less
1085
Indomethacin; except when specified elsewhere in this schedule
1089
Influenza and coryza vaccines; for injection; for nasal use
1090
Influenza vaccine; except when administered to a person 13 years of age or over by vaccinators, registered pharmacists, or registered intern pharmacists who have successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who comply with the immunisation standards of the Ministry of Health (but excluding vaccinators who have completed the Provisional Vaccinator Foundation Course)
1094
Insulin-like growth factors; except when specified elsewhere in this schedule
1100
Ipecacuanha; except when specified elsewhere in this schedule
1102
Ipratropium; except for nasal use
1108
Iron; except when specified elsewhere in this schedule
1115
Isoconazole; except when specified elsewhere in this schedule
1122
Isopropamide; except when specified elsewhere in this schedule
1136
Japanese encephalitis vaccine
1137
Juniperus sabina; at all strengths
1142
Ketoconazole; except when specified elsewhere in this schedule
1143
Ketoprofen; except when specified elsewhere in this schedule
1145
Ketotifen; except for ophthalmic use in medicines containing 0.025% or less
1155
Lansoprazole; except when specified elsewhere in this schedule
1164
Lauromacrogols; for injection
1178
Leucovorin; for injection
1185
Levocabastine; except for nasal or ophthalmic use
1186
Levocetirizine; except for oral use
1190
Levonorgestrel; except when specified elsewhere in this schedule; except in medicines for use as emergency post-coital contraception when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health; except when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister or Director-General to their distribution as medicines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme
1193
Lidocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatrists Board or by a dental therapist or an oral health therapist registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule
1195
Ligularia dentata; at all strengths
1199
Lindane; except for external use in medicines containing 2% or less
1207
Lithium; except when specified elsewhere in this schedule; except when present as an excipient in dermal medicines containing 0.25% or less
1209
Lodoxamide; except in medicines for ophthalmic use
1213
Loperamide; except when specified elsewhere in this schedule
1217
Loratadine; except when specified elsewhere in this schedule
1223
Lovastatin; except when present as an unmodified, naturally occurring substance in a food that has not been subject to a manufacturing process other than heating, freezing, drying, preserving, bottling, canning, or packaging in retort pouches
1237
Measles vaccine; except when administered, in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has consented to, by vaccinators, registered pharmacists, or registered intern pharmacists who have successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who comply with the immunisation standards of the Ministry of Health (but excluding vaccinators who have completed the Provisional Vaccinator Foundation Course)
1249
Meclozine; except when specified elsewhere in this schedule
1254
Mefenamic acid; except when specified elsewhere in this schedule
1259
Melanocyte stimulating compounds
1260
Melatonin; except when supplied in medicines for oral use containing 3 milligrams or less per immediate release dose unit, or 2 milligrams or less per modified release dose unit, when sold in the manufacturer’s original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist
1263
Melia azedarach; at all strengths
1267
Meningococcal vaccine; except when administered to a person 16 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course)
1279
Mepyramine; except when specified elsewhere in this schedule
1283
Mercurochrome; except when specified elsewhere in this schedule
1284
Mercury; except when specified elsewhere in this schedule
1307
Methdilazine; except for oral use
1316
Methoxamine; except when specified elsewhere in this schedule
1324
Methyl mercury; except in medicines containing 300 micrograms or less per litre or per kilogram
1325
Methyl salicylate; except for external use; except for internal use when present as an excipient in medicines containing 1.04% or less per dose form
1328
Methylene blue; for injection
1330
Methylhexanamine (1,3-dimethylamylamine (DMAA)); except when present as an unmodified, naturally occurring substance
1341
Metoclopramide; except when specified elsewhere in this schedule
1354
Miconazole; except when specified elsewhere in this schedule
1365
Minoxidil; except for dermal use in medicines containing 5% or less
1380
Mometasone; except when specified elsewhere in this schedule
1382
Monoclonal antibodies; except in pregnancy test kits
1387
Morphine; except when specified elsewhere in this schedule
1391
Mumps vaccine; except when administered, in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has consented to, by vaccinators, registered pharmacists, or registered intern pharmacists who have successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who comply with the immunisation standards of the Ministry of Health (but excluding vaccinators who have completed the Provisional Vaccinator Foundation Course)
1408
Naloxone; except when provided as part of an approved emergency kit for the treatment of opioid overdose
1411
Naproxen; except when specified elsewhere in this schedule
1418
Nebracetam (and its stereoisomers)
1440
Nicotine; except when specified elsewhere in this schedule; except in preparations for oromucosal or transdermal absorption; for nasal use except when sold from a smoking cessation clinic run under the auspices of a registered medical practitioner; in medicines other than for smoking cessation
1441
Nicotinic acid except nicotinamide; except when specified elsewhere in this schedule
1463
Nitrous oxide; when supplied for inhalation
1466
Nizatidine; except when specified elsewhere in this schedule
1469
Noopept (and its stereoisomers)
1477
Norethisterone; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister or Director-General to their distribution as medicines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme
1485
Nux vomica; except in medicines containing 1 milligram or less per litre or per kilogram of strychnine
1486
Nystatin; except when specified elsewhere in this schedule
1495
Oestradiol; except in medicines containing 10 micrograms or less per litre or per kilogram
1498
Oestrone; except in medicines containing 1 milligram or less per litre or per kilogram
1513
Omeprazole; except when specified elsewhere in this schedule
1518
Orlistat; except in medicines for weight control containing 120 milligrams or less per dose form
1523
Oseltamivir; except when specified elsewhere in this schedule
1536
Oxedrine; except in medicines containing 30 milligrams or less per recommended daily dose
1537
Oxetacaine; except for internal use
1538
Oxiconazole; except when specified elsewhere in this schedule
1539
Oxiracetam (and its stereoisomers)
1545
Oxybuprocaine; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
1552
Oxyphenisatin; at all strengths
1555
Oxytocin; except in medicines containing 1 microgram or less per litre or per kilogram
1565
Pancreatic enzymes; except in medicines containing 20 000 BP units or less of lipase activity
1569
Pantoprazole; except when specified elsewhere in this schedule
1571
Papaverine; for injection
1572
Paracetamol; except when specified elsewhere in this schedule
1582
Patent blue V; for injection when used in diagnostic procedures
1583
Patiromer sorbitex calcium
1598
Penciclovir; except when specified elsewhere in this schedule
1600
Pentaerythrityl tetranitrate
1607
Pentosan polysulfate sodium
1616
Permethrin; except in medicines containing 5% or less
1619
Pertussis (whooping cough) vaccine
1623
Phenacetin; except when present as an excipient
1625
Phenazone; except for external use
1633
Pheniramine; except when specified elsewhere in this schedule
1646
Phenylephrine; except when specified elsewhere in this schedule
1652
Pholcodine; except when specified elsewhere in this schedule
1653
Phosphodiesterase type 5 inhibitors; except when present as an unmodified, naturally occurring substance; except when specified elsewhere in this schedule
1660
Pilocarpine; except in medicines containing 0.025% or less
1683
Piroxicam; except for external use
1692
Pneumococcal vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds
1693
Podophyllotoxin; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 1%; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
1694
Podophyllum emodi; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 20% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
1695
Podophyllum peltatum; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 20% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
1699
Polyacrylamide; in injections or implants for tissue augmentation or cosmetic use
1701
Polylactic acid; in injections or implants for tissue augmentation or cosmetic use
1703
Polysulfated glycosaminoglycans; for injection except in intraocular viscoelastic products
1732
Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or an oral therapist registered with the Dental Council; except when specified elsewhere in this schedule
1741
Prochlorperazine; except when specified elsewhere in this schedule; except when sold for the treatment of nausea associated with emergency contraception by pharmacists or nurses accredited to sell levonorgestrel for emergency contraception
1742
Procyclidine; except for dermal use in medicines containing 5% or less
1743
Progesterone; except in medicines containing 1 milligram or less per litre or per kilogram
1749
Promethazine; except when specified elsewhere in this schedule
1752
Propamidine; except for ophthalmic use
1758
Propranolol; except in medicines containing 1 milligram or less per litre or per kilogram
1770
Proxymetacaine; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
1773
Pulmonaria spp; at all strengths
1777
Pyridoxal; except in medicines containing 200 milligrams or less per recommended daily dose
1778
Pyridoxamine; except in medicines containing 200 milligrams or less per recommended daily dose
1779
Pyridoxine; except in medicines containing 200 milligrams or less per recommended daily dose
1789
Quinine; except in medicines containing 50 milligrams or less per recommended daily dose
1794
Racetams; except when specified elsewhere in this schedule
1801
Ranitidine; except when specified elsewhere in this schedule
1810
Recombinant human epidermal growth factor
1811
Recombinant varicella zoster virus glycoprotein E antigen
1847
Rizatriptan; except when specified elsewhere in this schedule
1851
Rolipram (and its stereoisomers)
1866
Rubella vaccine; except when administered, in combination with measles and mumps vaccines in a combination product the supply of which the Minister of Health has consented to, by vaccinators, registered pharmacists, or registered intern pharmacists who have successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding vaccinators who have completed the Provisional Vaccinator Foundation Course)
1871
Sabadilla; except in preparations containing 10 milligrams or less of total alkaloids of schoenocaulon officinale per litre or per kilogram
1874
Safrole; for internal use except in medicines containing 0.1% or less
1883
Schoenocaulon officinale; except in preparations containing 10 milligrams or less of total alkaloids of schoenocaulon officinale per litre or per kilogram
1889
Selective androgen receptor modulators
1890
Seletracetam (and its stereoisomers)
1892
Selenium; except when specified elsewhere in this schedule; except for oral use in medicines containing 150 micrograms or less per recommended daily dose
1902
Sex hormones and all substances having sex hormone activity
1906
Sildenafil and its structural analogues; except sildenafil in medicines for oral use containing 100 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 12 solid dosage units for the treatment of erectile dysfunction in males aged 35–70 years by a registered pharmacist who has successfully completed a training programme endorsed by the Pharmaceutical Society of New Zealand Incorporated
1910
Silver sulfadiazine; except for external use in packs containing 50 grams or less
1919
Sodium cellulose phosphate; for internal use
1920
Sodium cromoglycate; except for nasal and ophthalmic use
1921
Sodium morrhuate; for injection
1924
Sodium phosphate; in oral laxative preparations
1925
Sodium polystyrene sulphonate
1926
Sodium tetradecyl sulphate; for injection
1927
Sodium zirconium cyclosilicate
1946
Staphylococcus aureus vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds
1948
Stenabolic (SR9009) and other synthetic REV-ERB agonists
1953
Stramonium; except for oral use when specified elsewhere in this schedule; except datura stramonium or datura tatula for smoking or burning
1954
Streptococcus beta-haemolyticus vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds
1962
Strychnos spp; except in medicines containing 1 milligram or less per litre or per kilogram of strychnine
1968
Sulconazole; except for dermal use
1969
Sulfacetamide; except for ophthalmic use in medicines containing 10% or less
1970
Sulfadiazine; except silver sulfadiazine for external use in pack sizes of 50 grams or less
1995
Sumatriptan; except when specified elsewhere in this schedule
2006
Tadalafil and its structural analogues
2015
Tanacetum vulgare; except in medicines containing 0.8% or less of oil of tansy
2037
Terbinafine; except when specified elsewhere in this schedule
2047
Testosterone; except in medicines containing 1 milligram or less per litre or per kilogram
2060
Theophylline; except when specified elsewhere in this schedule
2077
Thiourea; except in medicines containing 0.1% or less
2082
Thyrotrophin-releasing factor
2083
Thyroxine; except in medicines containing 10 micrograms or less per litre or per kilogram
2104
Tioconazole; except when specified elsewhere in this schedule
2134
Trametinib dimethyl sulfoxide
2149
Triamcinolone; except when specified elsewhere in this schedule
2154
Trichloroacetic acid; except for external use in medicines containing 12.5% or less for the treatment of warts other than anogenital warts
2156
Trichodesma africana; at all strengths
2165
Trimeprazine; except when specified elsewhere in this schedule
2167
Trimethoprim; except in medicines for oral use containing 300 milligrams or less per dose unit when sold in a pack of 3 solid dosage units to a woman aged 16–65 years for the treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the New Zealand College of Pharmacists’ training in the treatment of urinary tract infections
2172
Triparanol; at all strengths
2174
Triprolidine; except when specified elsewhere in this schedule
2177
Trometamol; for injection in medicines containing more than 3%
2178
Tropicamide; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
2182
Tryptophan; except in medicines containing 100 milligrams or less per recommended daily dose; except in parenteral nutrition replacement preparations
2201
Vaccines; except when specified elsewhere in this schedule
2211
Vardenafil and its structural analogues
2213
Varicella vaccine; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course)
2242
Vitamin A; except for internal use in medicines containing 3 milligrams or less of retinol equivalents per recommended daily dose; except in parenteral nutrition replacement preparations; except for external use in medicines containing 1% or less
2243
Vitamin D; except for external use; except for internal use in medicines containing 25 micrograms or less per recommended daily dose; except in parenteral nutrition replacement preparations
2264
Zinc; except for internal use in medicines containing 25 milligrams or less per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the Minister or the Director-General to their distribution as general sale medicines, when sold in the manufacturer’s original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except for external use when in medicines containing 5% or less; except in parenteral nutrition replacement preparations
2267
Zolmitriptan; except when specified elsewhere in this schedule
2271
Zoster immunoglobulin, human
Part 2 Restricted medicines
1
Adrenaline; in medicines containing 1% or less except in medicines for injection containing 0.02% or less
2
Alclometasone; for dermal use in medicines containing 0.05% or less and in packs containing not more than 30 grams that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack
3
Aminophylline; for oral use in liquid form in medicines containing 2% or less
4
Amorolfine; for external use in medicines containing more than 0.25%
5
Aspirin; in slow-release forms; in enteric coated forms containing more than 300 milligrams per dose form
6
Azatadine; for oral use in adults and children over 2 years of age
7
Azelastine; in medicines for ophthalmic use containing 0.05% or less
8
Brompheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
10
Butoconazole; for vaginal use
11
Chloramphenicol; for ophthalmic use; except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
12
Chlorbutol; except when specified elsewhere in this schedule
13
Chlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
14
Ciclopirox; for external use in medicines containing more than 2%; in preparations for application to the nails containing more than 8%
15
Cimetidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply
17
Clobetasone; for dermal use in medicines containing 0.05% or less and in packs containing not more than 30 grams that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack
18
Clotrimazole; for vaginal use
19
Cyclizine; for oral use other than in medicines used for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 6 dosage units; for oral use in medicines used for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
20
Cyproheptadine; for oral use
21
Dexchlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
22
Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged six years and over
23
Di-iodohydroxy quinoline; for vaginal use
24
Diclofenac; in solid dose form in medicines containing 25 milligrams or less and more than 12.5 milligrams per dose form in packs containing not more than 30 tablets or capsules
25
Dimenhydrinate; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule
26
Dimethindene; for oral use
27
Diphenhydramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
29
Doxylamine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
30
Econazole; for vaginal use
32
Famciclovir; in divided solid dosage forms for oral use containing 500 milligrams or less for the treatment of recurrent herpes labialis when sold in the manufacturer’s original pack containing up to 3 dosage units
34
Fluconazole; for oral use in medicines that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack containing 150 milligrams or less as a single dose for the treatment of vaginal candidiasis
35
Fluorides; for external use in liquid form in medicines containing 5.5 grams or less and more than 1 gram per litre or per kilogram and when sold in packs approved by the Minister or the Director-General for distribution as restricted medicines; for external use in non-liquid form in medicines containing 5.5 grams or less and more than 1 gram per litre or per kilogram, except in medicines containing 1.5 grams or less and more than 1 gram per litre or per kilogram; except when supplied to a dental professional registered with the Dental Council
36
Glucagon; except in medicines containing 100 micrograms or less per litre or per kilogram
37
Glyceryl trinitrate; for oral or sublingual use; for rectal use
38
Guaifenesin; for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing more than 10 days’ supply but not more than 30 days’ supply; except for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing not more than 10 days’ supply; except for oral use in medicines containing 2% or less or 200 milligrams or less per dose form
39
Haemophilus influenzae vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds
40
Hydrocortisone and hydrocortisone acetate but no other esters of hydrocortisone; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other active ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other active ingredient except 5% or less by weight of aciclovir and in a quantity of 2 grams or less or 2 millilitres or less per container in adults and children 12 years of age and older; in rectal medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or up to 12 suppositories per pack
41
Hyoscine butylbromide; for oral use in medicines containing not more than 20 milligrams per dose form and in packs containing not more than 10 tablets or capsules for the relief of muscle spasm of the gastrointestinal tract
42
Ibuprofen; for oral use in tablets or capsules containing up to 400 milligrams per dose form and in packs containing not more than 50 dose units and that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack labelled for use by adults or children over 12 years of age
44
Isoconazole; for vaginal use
45
Ketoprofen; in solid dose form containing 25 milligrams or less per dose form in packs of not more than 30 capsules or tablets
46
Lansoprazole; in divided solid dosage forms for oral use containing 15 milligrams or less with a maximum daily dose of 15 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over for the relief of heartburn when sold in the manufacturer’s original pack containing not more than 14 dosage units
47
Levonorgestrel; in medicines for use as emergency post-coital contraception when in packs containing not more than 1.5 milligrams
48
Macrogols; in oral preparations for bowel cleansing prior to diagnostic, medical, or surgical procedures
49
Malathion; except for external use in medicines containing 2% or less
51
Meclozine; in a pack size of up to 10 dosage units for the treatment of insomnia
52
Mepyramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
53
Methdilazine; for oral use
54
Metoclopramide; when compounded with paracetamol in packs of not more than 10 tablets or capsules for the treatment of nausea associated with migraine
55
Miconazole; for the treatment of oral candidiasis; for vaginal use
56
Nicotinic acid except nicotinamide; in medicines containing 250 milligrams or less but more than 100 milligrams per dose form; except in medicines containing 100 milligrams or less per dose form
57
Nicotinyl alcohol; except in medicines containing 100 milligrams or less per dose form
58
Nystatin; for the treatment of oral candidiasis; for vaginal use
59
Orlistat; in medicines for weight control containing 120 milligrams or less per dose form
60
Oseltamivir; in solid dosage forms for oral use containing 75 milligrams in a pack size of up to 10 dosage units for the treatment or prophylaxis of influenza in adults and children aged 13 years and older who have been exposed to the influenza virus
61
Oxiconazole; for vaginal use
62
Paracetamol; in modified-release forms containing 665 milligrams or less
63
Pheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
64
Pneumococcal vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds
65
Podophyllotoxin; for external use for the treatment of warts other than anogenital warts in medicines containing 1% or less and more than 0.5%; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
66
Podophyllum emodi; for external use for the treatment of warts other than anogenital warts in medicines containing 20% or less and more than 10% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
67
Podophyllum peltatum; for external use for the treatment of warts other than anogenital warts in medicines containing 20% or less and more than 10% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
68
Prochlorperazine; in packs containing not more than 10 tablets or capsules for the treatment of nausea associated with migraine
69
Promethazine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
70
Rizatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms, when in wafers containing 5 milligrams or less per wafer and when sold in a pack containing not more than 2 wafers approved by the Minister or the Director-General for distribution as a restricted medicine
71
Salicylic acid; except in medicines for dermal use containing 40% or less
73
Sodium phosphate; in oral preparations for bowel cleansing prior to diagnostic, medical, or surgical procedures
74
Sodium picosulphate; in oral preparations for bowel cleansing prior to diagnostic, medical, or surgical procedures
75
Staphyloccocus aureus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds
76
Stramonium; for oral use in liquid form; in solid dose form in medicines containing more than 0.3 milligrams per dose or more than 1.2 milligrams per recommended daily dose
77
Streptococcus beta-haemolyticus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds
78
Sulfacetamide; for ophthalmic use in medicines containing 10% or less
79
Sumatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms when in tablets containing 50 milligrams or less per tablet and when sold in a pack containing not more than 2 tablets that has received the consent of the Minister or the Director-General to its sale as a restricted medicine
80
Theophylline; in liquid form for oral use in medicines containing 2% or less
81
Tioconazole; for vaginal use
82
Triamcinolone; for buccal use in medicines containing 0.1% or less of triamcinolone acetonide and in pack sizes of 5 grams or less
83
Trimeprazine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
84
Triprolidine; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule
85
Zolmitriptan; in a pre-filled nasal spray device containing not more than 5 milligrams of zolmitriptan, for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms and when sold in a pack of not more than 2 devices approved by the Minister or the Director-General for distribution as a restricted medicine
Part 3 Pharmacy-only medicines
1
8-hydroxyquinoline and its non-halogenated derivatives; in medicines containing more than 1% of such substances; except for hydroxyquinoline sulphate for external use
2
Acetic acid and preparations containing more than 80% of acetic acid (CH3COOH); excluding its salts and derivatives
3
Acetylcysteine; for oral use in medicines containing more than 1 gram per recommended daily dose
4
Aciclovir; for external use for the treatment of herpes labialis except in medicines containing 5% or less and in tubes containing 10 grams or less
5
Aconitum spp; for oral use in packs containing 0.2 milligrams or less and more than 0.02 milligrams of total alkaloids; for dermal use in concentrations of 0.02% or less and in packs containing 0.2 milligrams or less and more than 0.02 milligrams of total alkaloids
6
Aloes; for internal use; except when obtained solely from the mucilaginous gel of the leaf
9
Amethocaine; for external use in medicines containing 10% or less and more than 2%; except in medicines for external use containing 2% or less
10
Amorolfine; in preparations for topical use; except in preparations for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
11
Antazoline; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
12
Atropa belladonna; for external use in medicines containing 0.03% or less of the alkaloids of belladonna; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of the alkaloids of belladonna or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of the alkaloids of belladonna
13
Atropine; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose; in medicines containing atropine sulphate for the treatment of organophosphorus poisoning either in packs of not more than 20 dose units containing 0.6 milligrams or less per dose unit or in injections in packs of not more than 5 vials containing 0.6 milligrams per millilitre; except when sold as an antidote in a device designed for self-injection from outlets licensed to sell organophosphorus poisons; except in medicines containing 300 micrograms or less per litre or per kilogram
14
Azelaic acid; for dermal use
15
Azelastine; in preparations for nasal use containing 0.15% azelastine hydrochloride or less; in topical eye preparations containing 0.05% or less
16
Beclomethasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 micrograms per actuation when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril) in a pack containing 200 actuations or less
17
Benzocaine; in preparations for topical use, other than eye drops, containing 10% or less of total anaesthetic substances except in dermal preparations containing 2% or less of total anaesthetic substances; in divided preparations containing 200 milligrams or less of total anaesthetic substances per dosage unit except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit
18
Benzoyl peroxide; for external use in medicines containing more than 5% and not more than 10%; except for medicines for external use containing 5% or less
19
Benzydamine; for external use except for oromucosal or topical use
21
Bifonazole; except when specified elsewhere in this schedule; except for dermal use in medicines for tinea pedis only or in shampoos containing 1% or less or when sold in practice by a podiatrist registered with the Podiatrists Board
22
Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjunctivitis (seasonal and perennial)
25
Brompheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing brompheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
26
Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril)
27
Carbetapentane; except in medicines containing 0.5% or less
29
Cetirizine; for oral use except in divided solid dosage forms for oral use containing 10 milligrams or less of cetirizine hydrochloride per dose form for the treatment of seasonal allergic rhinitis when sold in the manufacturer’s original pack containing not more than 5 days’ supply
31
Chlorbutol; in medicines containing 5% or less and more than 0.5%; except in medicines containing 0.5% or less
32
Chloroform; in medicines other than for anaesthesia containing more than 0.5%; except in medicines containing 0.5% or less
33
Chlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing chlorpheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
34
Ciclopirox; for external use in medicines containing 2% or less except when for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board; in preparations for application to the nails containing 8% or less
35
Cinchocaine; for external use in medicines containing 0.5% or less
37
Clotrimazole; for external use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
38
Cocaine; in medicines for oral use, containing not more than 0.1% of cocaine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, and when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine
40
Creosote; except in medicines containing 10% or less
41
Cresols; except in medicines containing 3% or less
42
Datura spp; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
43
Delphinium staphisagria; except in medicines containing 0.2% or less
44
Desloratadine; for oral use
45
Dexchlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing dexchlorpheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
46
Dextromethorphan; in liquid form containing more than 0.25% or in solid dose form containing more than 15 milligrams per dose form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of the symptoms of cough and cold in children aged 6–12 years; except in liquid form containing 0.25% or less in solid dose form containing 15 milligrams or less per dose form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams
47
Dibrompropamidine; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
48
Diclofenac; in solid dose form in medicines containing 12.5 milligrams or less per dose form in packs containing not more than 30 tablets or capsules and with a recommended daily dose of not more than 75 milligrams
49
Diphenoxylate; in liquid form containing in each millilitre not more than 0.5 milligrams of diphenoxylate calculated as base and not less than 5 micrograms of atropine sulphate; in solid dose form containing not more than 2.5 milligrams of diphenoxylate calculated as base and not less than 5 micrograms of atropine sulphate
50
Dimenhydrinate; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults or children over 2 years of age except when sold at a transport terminal or aboard a ship or an aircraft
51
Diphenhydramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing diphenhydramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults and children over 2 years of age except when sold at a transport terminal or aboard a ship or an aircraft
52
Doxylamine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing doxylamine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
53
Duboisia leichhardtii; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
54
Duboisia myoporides; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
55
Econazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
56
Esomeprazole; in oral preparations containing 20 milligrams or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days’ supply
58
Ether; in medicines containing more than 10%; except in medicines containing 10% or less
59
Etofenamate; for external use
60
Famotidine; for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply
61
Felbinac; for external use
62
Fexofenadine; for oral use except for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 180 milligrams when sold in the manufacturer’s original pack containing 5 dosage units or less and not more than 5 days’ supply
63
Fluorides; for internal use in medicines containing 0.5 milligrams or less per dose unit; except in parenteral nutrition replacement preparations; for external use in liquid form in medicines containing 1 gram or less per litre or per kilogram and when sold in packs approved by the Minister or the Director-General for distribution as pharmacy-only medicines except in medicines containing 220 milligrams or less per litre or per kilogram and in packs containing not more than 120 milligrams of total fluoride; except when supplied to any dental professional registered with the Dental Council; except in medicines containing 15 milligrams or less per litre or per kilogram
64
Flurbiprofen; in locally acting oromucosal preparations containing 10 milligrams or less per dosage unit
65
Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose)
66
Folic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose; except for oral use in medicines containing 500 micrograms or less per recommended daily dose; except in parenteral nutrition replacement preparations
67
Folinic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose; except for oral use in medicines containing 500 micrograms or less per recommended daily dose
68
Formaldehyde; except in medicines containing 5% or less
69
Gelsemium sempervirens; except in medicines containing 1 milligram or less per litre or per kilogram
71
Hexachlorophane; in medicines containing 3% or less but more than 0.75%; except in medicines containing 0.75% or less
72
Hydrocortisone and hydrocortisone acetate but no other esters of hydrocortisone; for dermal use in medicines containing 0.5% or less by weight of hydrocortisone base with no other active ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; in rectal medicines containing 0.5% or less by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or 12 suppositories or fewer per pack
73
Hydrocyanic acid; for oral use in packs containing 5 milligrams or less and more than 0.5 milligrams; except in medicines containing 1 microgram or less per litre or per kilogram; except for oral use in packs containing 0.5 milligrams or less
74
Hydroquinone; for external use in medicines containing 2% or less except in hair preparations containing 1% or less
75
Hyoscine; for transdermal use in medicines containing 2 milligrams or less of total solanaceous alkaloids per dose unit; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
76
Hyoscyamine; for external use in medicines containing 0.03% or less of total solanaceous alkaloids; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
77
Hyoscyamus niger; for oral use in liquid form in medicines containing 0.03% or less (300 micrograms or less of total solanaceous alkaloids per litre or per kilogram) and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose except in packs containing 30 micrograms or less of total solanaceous alkaloids
78
Ibuprofen; for oral use in liquid form with a recommended daily dose of not more than 1.2 grams for the relief of pain and reduction of fever or inflammation when sold in the manufacturer’s original pack containing not more than 8 grams; for oral use in solid dose form containing not more than 200 milligrams per dose form and with a recommended daily dose of not more than 1.2 grams when sold in the manufacturer’s original pack containing not more than 100 dose units; except in divided solid dosage forms for oral use containing 200 milligrams or less per dose form with a recommended daily dose of not more than 1.2 grams and when sold in the manufacturer’s original pack containing not more than 25 dose units; except for external use
80
Indomethacin; for external use in medicines containing 1% or less; except in medicines containing 1 milligram or less per litre or per kilogram
81
Iodine; except for external use in medicines containing 2.5% or less; for internal use in medicines containing less than 300 micrograms per recommended daily dose
82
Ipecacuanha; in medicines containing 0.2% or less of emetine and 40 micrograms or more of ipecacuanha alkaloids per recommended dose for the treatment of the symptoms of cough and cold in children aged 6–12 years; except in medicines containing less than 40 micrograms of ipecacuanha alkaloids per recommended dose for the treatment of the symptoms of cough and cold in children aged 6–12 years
83
Ipomoea spp; except ipomoea batatas
84
Ipratropium; for nasal use
85
Iron; for oral use either in medicines containing more than 24 milligrams per recommended daily dose or in medicines containing more than 5 milligrams per dose unit and more than 750 milligrams of iron per pack; except in parenteral nutrition replacement preparations; except for oral use in medicines containing 24 milligrams or less per recommended daily dose in medicines containing not more than 5 milligrams per dose unit; except for oral use in medicines containing 24 milligrams or less per recommended daily dose in medicines containing more than 5 milligrams per dose unit in packs containing not more than 750 milligrams of iron
86
Isoconazole; for dermal use except when sold in practice by a podiatrist registered with the Podiatrists Board
87
Isopropamide; for dermal use in preparations containing 2% or less
89
Ketoconazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board; except in medicines for treatment of the scalp containing 1% or less
90
Ketotifen; for ophthalmic use in medicines containing 0.025% or less except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
91
Leucovorin; in medicines containing more than 500 micrograms per recommended daily dose
92
Levocabastine; for nasal use; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
93
Levocetirizine; for oral use
94
Lignocaine; for urethral use; for external use in medicines containing 10% or less and more than 2%
95
Lindane; for external use in medicines containing 2% or less
96
Lithium; for dermal use in medicines containing 1% or less but more than 0.01%; except for dermal use in medicines containing 0.01% or less
97
Lobelia inflata; except in medicines for smoking or burning
98
Lobeline; except when in medicines for smoking or burning
99
Lodoxamide; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
100
Loperamide; in packs containing not more than 20 tablets or capsules; except in divided solid dosage forms for oral use containing 2 milligrams or less of loperamide per dosage form when sold in a pack containing not more than 8 dosage forms approved by the Minister or the Director-General for distribution as a general sales medicine for the symptomatic treatment of acute non-specific diarrhoea
101
Loratadine; for oral use; except in divided solid dosage forms for oral use containing 10 milligrams or less per dose form for the treatment of seasonal allergic rhinitis when sold in the manufacturer’s original pack containing not more than 10 days’ supply
102
Macrogols; in preparations for oral use as a liquid concentrate for laxative use
104
Meclozine; in a sealed container of not more than 12 tablets or capsules for the prevention or treatment of travel sickness except when sold at a transport terminal or aboard a ship or aircraft
105
Mefenamic acid; in solid dose form in packs containing not more than 30 tablets or capsules for the treatment of dysmenorrhoea
106
Mepyramine; for dermal use; except for external use in medicines containing 2% or less in packs not exceeding 25 grams
107
Mercuric oxide; for ophthalmic use
108
Mercurochrome; in preparations for external use containing 2% or less
109
Mercury; for external use in medicines containing 0.5% or less; except in medicines containing 1 milligram or less per litre or per kilogram
110
Methoxamine; for external use in medicines containing more than 1%; except for external use in medicines containing 1% or less
113
Miconazole; for external use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
114
Minoxidil; for dermal use in medicines containing 5% or less
115
Mometasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 micrograms per actuation when the maximum recommended daily dose is no greater than 200 micrograms (as a single dose) in a pack containing 200 actuations or less
116
Morphine; in medicines for oral use containing not more than 0.2% of morphine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine
117
Naphazoline; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
118
Naproxen; in solid dose form containing 250 milligrams or less per dose form in packs of not more than 30 tablets or capsules
120
Nicotine; for inhalation except when sold from a smoking cessation clinic run under the auspices of a registered medical practitioner, nurse, pharmacist, or psychologist
121
Nizatidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply
123
Nystatin; for dermal use except when sold in practice by a podiatrist registered with the Podiatrists Board; except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
124
Omeprazole; in divided solid dosage forms for oral use containing 20 milligrams or less with a maximum daily dose of 20 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer’s original pack containing not more than 28 dosage units
125
Opium; in medicines for oral use containing not more than 0.2% of morphine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine
126
Oxetacaine; for internal use
127
Oxiconazole; for dermal use except in medicines for tinea pedis only
128
Oxymetazoline; except for nasal use when sold at an airport; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except for nasal use in medicines containing 0.05% or less when sold in the manufacturer’s original pack with a pack size of 20 millilitres or less
129
Pantoprazole; in divided solid dosage forms for oral use containing 20 milligrams or less with a maximum daily dose of 20 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer’s original pack containing not more than 28 dosage units
130
Papaverine; except for injection
131
Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams
132
Paraformaldehyde; except in medicines containing 5% or less
133
Penciclovir; for external use for the treatment of herpes labialis; except in medicines for external use containing 1% or less in a pack containing 10 grams or less for the treatment of herpes labialis
135
Phenazone; for external use
136
Pheniramine; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing pheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
137
Phenol; except in medicines other than for injection containing 3% or less
138
Phenylephrine; for nasal use in medicines containing more than 1%; for ophthalmic use in medicines containing 5% or less and more than 1%; for oral use in medicines containing more than 50 milligrams per recommended daily dose or in packs containing more than 250 milligrams of phenylephrine per pack; in medicines for the treatment of the symptoms of cough and cold in children aged 6–12 years; except for nasal or ophthalmic use in medicines containing 1% or less; except for oral use in medicines containing 50 milligrams or less per recommended daily dose and in packs containing 250 milligrams or less of phenylephrine per pack
139
Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine
141
Podophyllotoxin; for external use for the treatment of warts other than anogenital warts in medicines containing 0.5% or less; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
142
Podophyllum emodi; for external use for the treatment of warts other than anogenital warts in medicines containing 10% or less of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
143
Podophyllum peltatum; for external use for the treatment of warts other than anogenital warts in medicines containing 10% or less of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram
144
Potassium; for internal use: in slow-release or enteric coated forms; except for internal use: in medicines containing 100 milligrams or less per recommended dose; in medicines containing more than 100 milligrams per recommended dose except in medicines for oral rehydration therapy, parenteral nutrition replacement, or dialysis; except in glucosamine sulphate complexed products containing 600 milligrams or less of potassium chloride per recommended dose; except for external use
145
Potassium chlorate; except in medicines containing 10% or less
146
Prilocaine; for dermal use in medicines containing 10% or less of local anaesthetic substances
147
Procyclidine; for dermal use in medicines containing 5% or less
148
Promethazine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing promethazine or when at least 1 of the other active ingredients is a sympathomimetic decongestant; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults and children over 2 years of age except when sold at a transport terminal or aboard a ship or aircraft
149
Propamidine; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
151
Pyrethrins; except in medicines containing 10% or less
152
Pyrithione zinc; except in medicines for treatment of the scalp containing 2% or less
153
Ranitidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner when sold in the manufacturer’s original pack containing not more than 14 days’ supply; except in medicines containing 300 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 7 days’ supply
155
Selenium; for oral use in medicines containing 300 micrograms or less and more than 150 micrograms per recommended daily dose; for external use except in medicines containing 3.5% or less of selenium sulphide
157
Silver; except in oral solutions containing 0.3% or less or other medicines containing 1% or less
158
Silver sulfadiazine; for external use in pack sizes of 50 grams or less
159
Sodium cromoglycate; for nasal use; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
160
Sodium nitrite; except for use as an excipient
161
Sodium picosulphate; in oral laxative preparations
162
Squill; except in medicines containing 1% or less
163
Stramonium; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids
164
Sulconazole; for dermal use
165
Sulfadiazine, silver; for external use in pack sizes of 50 grams or less
166
Terbinafine; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
168
Tetrahydrozoline; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
170
Tioconazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
172
Triamcinolone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age and when in aqueous nasal sprays delivering up to 55 micrograms per actuation when the maximum recommended daily dose is no greater than 220 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine
173
Trimeprazine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing trimeprazine or when at least 1 of the other therapeutically active ingredients is a sympathomimetic decongestant
174
Triprolidine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing triprolidine or when at least 1 of the other active ingredients is a sympathomimetic decongestant
177
Xylenols; except in medicines containing 3% or less
178
Xylometazoline; except for nasal use when sold at an airport; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board
179
Zinc chloride; for dermal use in medicines containing more than 5%